Glaucoma Drainage Device Surgery Outcomes in Children With Uveitic Glaucoma.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
07 2023
Historique:
received: 08 03 2020
revised: 31 01 2023
accepted: 02 02 2023
medline: 6 6 2023
pubmed: 24 2 2023
entrez: 23 2 2023
Statut: ppublish

Résumé

To evaluate outcomes of glaucoma drainage device (GDD) implantation children with uveitic glaucoma. Retrospective interventional case series. Success was defined as intraocular pressure (IOP) ≥5 and ≤21 mm Hg. Failure was defined at final follow-up when the IOP was outside the success criterion, and visual function was no perception of light or if further glaucoma surgery (excluding removal of intraluminal stent suture or needling) was required. Fifty eyes of 36 children with uveitic glaucoma underwent GDD implantation. Mean age at surgery was 10.1±3.1 years (range 5-17) with a mean follow-up of 113±61 months (range 8-228). Mean cumulative probabilities of success (95% CI) were 0.98 (0.86-1.00) at 1 year, 0.87 (0.73-0.94) at 5 years, and 0.59 (0.32-0.78) at 15 years. Fourteen tubes were classified as failed, with 12 due to uncontrolled IOP (11 eyes required a second GDD); 1 eye, removal of the tube due to plate exposure; and 1 eye, lost light perception. Postoperative complications occurred in 36% of patients and included hypotony (22%), tube exposure (6%), tube obstruction (4%), corneal decompensation (2%), and cystoid macular edema (2%). Visual acuity remained stable (preoperation 0.35±0.42 vs postoperation 0.45±0.67, P = .49). IOP was significantly reduced from 31.4±7.5 mm Hg to 14.4±5.1 mm Hg (P < .0001) as were the number of glaucoma medications 3.5±1.0 vs 1.1±1.3 (P < .0001). Refractory pediatric uveitic glaucoma can be treated successfully by GDD implantation. Further interventions to manage consequences of glaucoma or the underlying disease are common, and visual function is maintained in the majority of cases.

Identifiants

pubmed: 36822573
pii: S0002-9394(23)00050-8
doi: 10.1016/j.ajo.2023.02.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5-11

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Evangelia Gkaragkani (E)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.).

Hari Jayaram (H)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom (H.J., C.P., J.B., P.T.K., J.C.).

Maria Papadopoulos (M)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.).

Carlos Pavesio (C)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom (H.J., C.P., J.B., P.T.K., J.C.).

John Brookes (J)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom (H.J., C.P., J.B., P.T.K., J.C.).

Peng T Khaw (PT)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom (H.J., C.P., J.B., P.T.K., J.C.).

Yasmine M El Sayed (YM)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.).

Jonathan Clarke (J)

Moorfields Eye Hospital (E.G., H.J., M.P., C.P., J.B., P.T.K., Y.M.E.S., J.C.); NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom (H.J., C.P., J.B., P.T.K., J.C.). Electronic address: jonathan.clarke8@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH